MedWatch

Horizon Therapeutics to make blockbuster out of Genmab drug in 2021

Tepezza can already boast one of the best launches ever for a rare disease drug, and current owner company Horizon Therapeutics forecasts that the drug, developed in Genmab's labs, will sell for more than a billion US dollars in 2021.

Photo: PR / Genmab

US-based biopharmaceutical company Horizon Therapeutics is pulling out the big guns to market its rare disease drug, Tepezza, originally developed in the laboratories of Danish biotech firm Genmab.

This drug treats Graves' orbitopathy. No approved therapy in existence targets this particular disease. Consequently, the drug has had a phenomenal initial run since it was launched in early 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs